和元生物技术（上海）股份有限公司2025年年度业绩预亏公告

Core Viewpoint - The company, He Yuan Biotechnology (Shanghai) Co., Ltd., anticipates a net loss for the year 2025, although the loss is expected to be reduced compared to the previous year, indicating a potential improvement in financial performance despite ongoing challenges in the industry [2][4]. Group 1: Performance Forecast - The company expects a net profit attributable to shareholders of the parent company to be between -237 million to -195 million yuan for 2025, representing a reduction in loss of 84.81 million to 126.81 million yuan compared to the previous year, with a decrease in loss margin of 26.35% to 39.41% [2][4]. - The anticipated net profit, excluding non-recurring gains and losses, is projected to be between -244 million to -201 million yuan, reflecting a reduction in loss of 91.91 million to 134.91 million yuan year-on-year, with a decrease in loss margin of 27.36% to 40.16% [2][4]. Group 2: Previous Year Performance - In 2024, the total profit was -312.63 million yuan, with a net profit attributable to shareholders of the parent company at -321.81 million yuan, and a net profit excluding non-recurring gains and losses at -335.91 million yuan [6]. Group 3: Reasons for Performance Changes - The company is focusing on its core business in cell and gene therapy CRO/CDMO, leveraging national and industry development policies to strategically position itself in the regenerative medicine application field. The operational strategy emphasizes enhancing customer resource reserves, brand influence, and industry development [8]. - Despite an overall increase in revenue across various business segments, the CDMO business continues to face challenges such as insufficient downstream investment and low customer order prices, leading to significant losses [9]. - The company has conducted preliminary impairment tests on inventory, long-term assets, and contract orders due to the ongoing losses in the CDMO business, which has impacted the current net profit [10].